GWP42003-P + Placebo

Phase 3Terminated

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Seizures Associated With EMAS

Conditions

Seizures Associated With EMAS

Trial Timeline

Oct 31, 2022 → Sep 28, 2023

NCT ID

NCT05288283

About GWP42003-P + Placebo

GWP42003-P + Placebo is a phase 3 stage product being developed by Jazz Pharmaceuticals for Seizures Associated With EMAS. The current trial status is terminated. This product is registered under clinical trial identifier NCT05288283. Target conditions include Seizures Associated With EMAS.

What happened to similar drugs?

6 of 20 similar drugs in Seizures Associated With EMAS were approved

Approved (6) Terminated (2) Active (13)

🔄E2007EisaiPhase 3

🔄perampanel + perampanel + perampanel + PlaceboEisaiPhase 3

🔄Zonisamide + PlaceboEisaiPhase 3

🔄E2007 (perampanel) + E2007 (perampanel) + PlaceboEisaiPhase 3

🔄Perampanel + PlaceboEisaiPhase 3

🔄E2007 (perampanel) + E2007 (perampanel) + PlaceboEisaiPhase 3

✅Adjunctive Zonisamide + Replacement with ZonisamideEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05288283	Phase 3	Terminated	Oct 31, 2022	Sep 28, 2023	Seizures Associated With EMAS
NCT04745026	Phase 2	Completed	May 31, 2021	Dec 21, 2023	Autism Spectrum Disorder
NCT04421456	Phase 2	Terminated	Aug 18, 2020	Mar 16, 2022	Schizophrenia
NCT03848832	Phase 3	Terminated	Jul 29, 2019	Jan 21, 2021	Rett Syndrome
NCT02607891	Phase 2	Completed	Nov 9, 2016	Oct 2, 2018	Epilepsy
NCT02544763	Phase 3	Completed	Apr 6, 2016	Feb 26, 2019	Tuberous Sclerosis Complex

Competing Products

20 competing products in Seizures Associated With EMAS

See all competitors

Product	Company	Stage	Hype Score
E2007	Eisai	Phase 3	40
Perampanel	Eisai	Pre-clinical	26
perampanel + perampanel + perampanel + Placebo	Eisai	Phase 3	40
perampanel	Eisai	Phase 2	35
Perampanel	Eisai	Pre-clinical	26
Zonisamide + Placebo	Eisai	Phase 3	40
zonisamide	Eisai	Pre-clinical	26
E2007 (perampanel) + E2007 (perampanel) + Placebo	Eisai	Phase 3	40
Perampanel + Placebo	Eisai	Phase 3	40
E2007 (perampanel) + E2007 (perampanel) + Placebo	Eisai	Phase 3	40
Adjunctive Zonisamide + Replacement with Zonisamide	Eisai	Approved	43
Fycompa	Eisai	Pre-clinical	26
Zonisamide + Placebo	Eisai	Phase 3	40
Fycompa	Eisai	Pre-clinical	26
Rufinamide	Eisai	Phase 3	32
Eslicarbazepine Acetate tablets	Eisai	Pre-clinical	26
Perampanel	Eisai	Pre-clinical	26
Perampanel	Eisai	Pre-clinical	26
Perampanel	Eisai	Approved	43
Perampanel + Perampanel	Eisai	Pre-clinical	26